BioLife Solutions has undergone a strategic pivot, divesting freezer businesses to streamline into an asset-light consumables model, evidenced by debt falling to $15.7M and D/E of 0.04 in 2026Q2. Revenue rebounded 12% YoY to $28.5M, but operating margin remain...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | $0.91+2812.0% vs $0.03 | $28M+2.4% vs $28M |
Q2 2026 May 7, 2026 | $0.04+300.0% vs $0.01 | $28M+7.2% vs $26M |
Q1 2026 Feb 26, 2026 | $0.04+300.0% vs -$0.02 | $25M+2.9% vs $24M |
Q4 2025 Nov 6, 2025 | $0.04+1900.0% vs $0.00 | $28M+9.4% vs $26M |
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 11, 2026Insiders may stand to receive substantial financial be
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
Bank of New York Mellon Corp bought a new position in shares of BioLife Solutions, Inc. (NASDAQ: BLFS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 229,109 shares of the medical equipment provider's stock, valued at
BioLife Solutions (NASDAQ: BLFS - Get Free Report) and Qiagen (NYSE: QGEN - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability. Institutional and Insider Ownership 93.2% of BioLife Solutions shares
Benchmark BLFS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioLife Solutions, Inc. (BLFS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $37.74 | $1.84B | -150.96 | 16.97% | -12.61% | -3.37% | — | |
| $9.20 | $2.45B | -29.68 | 18.96% | -66.74% | -38.36% | — | |
| $34.09 | $1.57B | -27.94 | 3.55% | -20.02% | -7.56% | — | |
| $17.49 | $881.54M | 12.49 | -24.47% | -19.45% | -7.25% | — | |
| $184.53 | $10.41B | 214.57 | 16.36% | 5.29% | 1.98% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — |
BioLife Solutions, Inc. (BLFS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioLife Solutions, Inc. (BLFS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Aug 3, 2026·SEC
Jul 22, 2026·SEC
Get notified when BLFS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioLife Solutions, Inc. (BLFS) stock FAQ — growth, dividends, profitability & financials explained
BioLife Solutions, Inc. (BLFS) reported $102.8M in revenue for fiscal year 2025. This represents a 656% increase from $13.6M in 1995.
BioLife Solutions, Inc. (BLFS) grew revenue by 17.0% over the past year. This is strong growth.
Yes, BioLife Solutions, Inc. (BLFS) is profitable, generating $50.4M in net income for fiscal year 2025 (-12.6% net margin).
BioLife Solutions, Inc. (BLFS) has a return on equity (ROE) of -3.4%. Negative ROE indicates the company is unprofitable.
BioLife Solutions, Inc. (BLFS) had negative free cash flow of $0.9M in fiscal year 2025, likely due to heavy capital investments.
